Neurocrine Biosciences, Inc. (NASDAQ: NBIX) on Tuesday, plunged -0.36% from the previous trading day ,before settling in for the closing price of $139.44. Within the past 52 weeks, NBIX’s price has moved between $89.04 and $148.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 34.77% over the past five years. The company achieved an average annual earnings per share of 103.77%. With a float of $96.92 million, this company’s outstanding shares have now reached $98.70 million.
Let’s look at the performance matrix of the company that is accounted for 1400 employees.
Neurocrine Biosciences, Inc. (NBIX) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Neurocrine Biosciences, Inc. is 2.60%, while institutional ownership is 92.57%. The most recent insider transaction that took place on Apr 01 ’24, was worth 37,346. In this transaction Chief Regulatory Officer of this company sold 272 shares at a rate of $137.30, taking the stock ownership to the 7,507 shares. Before that another transaction happened on Mar 21 ’24, when Company’s Chief Regulatory Officer sold 5,000 for $145.06, making the entire transaction worth $725,320. This insider now owns 7,507 shares in total.
Neurocrine Biosciences, Inc. (NBIX) Latest Financial update
As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported $1.44 earnings per share (EPS) for the period topping the consensus outlook (set at $1.14) by $0.3. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 103.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.00% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Trading Performance Indicators
Neurocrine Biosciences, Inc. (NBIX) is currently performing well based on its current performance indicators. A quick ratio of 2.40 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.33. Likewise, its price to free cash flow for the trailing twelve months is 38.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.43, a number that is poised to hit 1.06 in the next quarter and is forecasted to reach 6.85 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc. (NBIX)
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) saw its 5-day average volume 0.66 million, a negative change from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 65.26%. Additionally, its Average True Range was 3.95.
During the past 100 days, Neurocrine Biosciences, Inc.’s (NBIX) raw stochastic average was set at 76.73%, which indicates a significant increase from 36.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.51% in the past 14 days, which was lower than the 24.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $137.24, while its 200-day Moving Average is $118.79. Nevertheless, the first resistance level for the watch stands at $140.93 in the near term. At $142.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $144.38. If the price goes on to break the first support level at $137.48, it is likely to go to the next support level at $136.01. The third support level lies at $134.03 if the price breaches the second support level.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Key Stats
Market capitalization of the company is 13.83 billion based on 99,507K outstanding shares. Right now, sales total 1,887 M and income totals 249,700 K. The company made 515,200 K in profit during its latest quarter, and 147,700 K in sales during its previous quarter.
